Filing Flows › Syndax Pharmaceuticals (SNDX) › Collaboration Revenue revenue
Syndax Pharmaceuticals (SNDX) Collaboration Revenue revenue by quarter
Syndax Pharmaceuticals' Collaboration Revenue revenue was $22.6M in Q3 2026 (third quarter 2026), +25% from Q2 2026. Over the last 5 quarters it ranged from $9.4M (Q2 2025) to $22.6M (Q3 2026).
| Quarter | Collaboration Revenue revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $22.6M | +25% | +63% |
| Q2 2026 | $18.1M | +13% | +93% |
| Q1 2026 | $15.9M | +15% | — |
| Q3 2025 | $13.9M | +48% | — |
| Q2 2025 | $9.4M | — | — |
Q3 2026 at a glance
Syndax Pharmaceuticals, Q3 2026: revenue $83.3M (+82% year over year), operating margin -50.3%, net loss $49.4M, operating cash flow −$27.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Syndax Pharmaceuticals' Collaboration Revenue revenue?
Syndax Pharmaceuticals' Collaboration Revenue revenue was $22.6M in Q3 2026 (third quarter 2026), +25% from Q2 2026.
How has Syndax Pharmaceuticals' Collaboration Revenue revenue changed?
Over the last 5 quarters it ranged from $9.4M (Q2 2025) to $22.6M (Q3 2026).
Q3 2026 results → · How Syndax Pharmaceuticals makes money →